RUNX1 and acute myeloid leukemia: More importantly, two independent studies identified somatic RUNX1 mutations in 2021 as the most common mutations in pDC-AML, detected in more than 70% of cases, whereas it was detected in 5–15% of AML and absent in BPDCN [102,103,108,109].